Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments

Wonju Lee, Sang Min Lee, Sang Taek Jung

Research output: Contribution to journalReview articlepeer-review

Abstract

The complement system is a crucial part of the innate immune response, providing defense against invading pathogens and cancer cells. Recently, it has become evident that the complement system plays a significant role in anticancer activities, particularly through complement-dependent cytotoxicity (CDC), alongside antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). With the discovery of new roles for serum complement molecules in the human immune system, various approaches are being pursued to develop CDC-enhanced antibody therapeutics. In this review, we focus on successful antibody engineering strategies for enhancing CDC, analyzing the lessons learned and the limitations of each approach. Furthermore, we outline potential pathways for the development of antibody therapeutics specifically aimed at enhancing CDC for superior therapeutic efficacy in the future.

Original languageEnglish
Pages (from-to)637-648
Number of pages12
JournalBioDrugs
Volume37
Issue number5
DOIs
Publication statusPublished - 2023 Sept

Bibliographical note

Funding Information:
This research was supported by the Korea Drug Development Fund funded by the Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (HN21C0103, Republic of Korea). We are also grateful for support from grants from the Basic Science Research Program (RS-2023-00245059 and 2022R1A4A2000827) through the National Research Foundation of Korea funded by the Ministry of Science and ICT.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments'. Together they form a unique fingerprint.

Cite this